1-(4-propylphenyl)-1H-imidazole | 502656-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-propylphenyl)-1H-imidazole
• 英文别名: 1-(4-propylphenyl)imidazole
• CAS: 502656-75-9
• 化学式: C₁₂H₁₄N₂
• 分子量: 186.257
• InChiKey: WOPARNADUHOTNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  咪唑 、 4-丙基溴苯 在 8-羟基-1,2,3,4-四氢喹啉 、 caesium carbonate 、 copper(I) bromide 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 以84%的产率得到1-(4-propylphenyl)-1H-imidazole
  参考文献：
  名称：

  1,2,3,4-四氢-8-羟基喹啉促进的铜催化的氮亲核试剂与芳基溴化物的偶联。

  摘要：

  基于2-氨基苯酚的显着加速作用，开发了三个衍生自2-氨基苯酚的配体。使用1,2,3,4-四氢-8-羟基喹啉作为新型，简单且通用的配体，可在温和条件下有效地进行含氮亲核试剂与芳基溴的铜催化偶联反应。

  DOI：

  10.1021/jo8015488

文献信息

• ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：SCHAEFER Matthias

  公开号：US20110152290A1

  公开（公告）日：2011-06-23

  The present invention relates to compounds of the formula I, wherein A, Y, Z, R 3 to R 6 , R 20 to R 22 and R 50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA 1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A、Y、Z、R3至R6、R20至R22和R50具有所述权利要求中指示的含义，这些化合物是有价值的药物活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也称为LPA1受体，可用于治疗动脉粥样硬化、心肌梗塞和心力衰竭等疾病。本发明还涉及制备式I化合物的方法、它们的用途以及包含它们的药物组合物。
• Fused Pyridone M1 Receptor Positive Allosteric Modulators
  申请人：Beshore Douglas C.

  公开号：US20100324088A1

  公开（公告）日：2010-12-23

  The present invention is directed to fused pyridone compounds of formula (I) (I) that are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的熔合吡啶酮化合物（I），它们是M1受体正向变构调节剂，并且在M1受体参与的疾病治疗中有用，例如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的药物组合物，以及在治疗M1受体介导的疾病中使用这些化合物和组合物的方法。
• 6-11 BICYCLIC KETOLIDE DERIVATIVES
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：EP1506214B1

  公开（公告）日：2010-01-20
• EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF
  申请人：XIAMEN SINOPEG BIOTECH CO., LTD

  公开号：US20180214561A1

  公开（公告）日：2018-08-02

  Disclosed are an eight-arm polyethylene glycol (PEG) derivative (formula I), production method therefor and modified bio-related substance thereby. Wherein, one tetravalent group U together with four trivalent groups E c form a highly symmetrical octavalent group CORE 0 ; L c connects the octavalent group to eight PEG chains having polydispersity or monodispersity and having n 1 to n 8 as the degree of polymerization thereof; the terminal of one PEG chain is connected to at least one functional group F (k≥1); said PEG chain and F therebetween can be directly connected (g=0) or be indirectly connected via a linking group L 0 to a terminal end-branching group G (g=1); the latter provides more reactive sites for binding more drug molecules and increases the drug loading. The eight-arm polyethylene glycol derivative has a centrosymmetric or approximately centrosymmetric structure, and leads to more precise control of the molecular weight in large-scale production and much narrower distribution of molecular weight for products. The modified bio-related substance thereby has a more uniform and controllable performance.
• US8022215B2
  申请人：——

  公开号：US8022215B2

  公开（公告）日：2011-09-20